It was just last month, with the Covid-19 situation having calmed down in Kyiv, that Ivan Kondratov had been able to return to his office a couple days per week. He managed a slew of medicinal chemistry projects, including the building of “target libraries” for clients, mostly large biopharma companies around the world.
His employer, Enamine, had become a pillar of global drug development, its Rolodex of clients steadily growing along with its catalog of chemical compounds for drugmakers to test in creating potential treatments.
But on Feb. 24, all of that came to a halt as Kondratov and hundreds of thousands of other Ukrainians were stunned awake by the sound of explosions. And everything changed for the chemists and scientists.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
